Biotech & Pharma · Week of Oct 26, 2026
Cancer diagnostics and early trial data: the week in biotech
Oncology diagnostics and early clinical data led a week otherwise filled with Q3 results notices, a dividend and conference plans.
Cancer detection and treatment data headed the week's releases. Abbott launched a whole-genome sequencing version of its Oncodetect molecular residual disease test, and Anixa Biosciences reported completing treatment of a fifth cohort in its ovarian cancer CAR-T trial. Outside oncology, Climb Bio presented initial Phase 2 PrisMN data for budoprutug, its anti-CD19 antibody, at ASN Kidney Week 2026.
The rest of the week was largely corporate calendar items ahead of third-quarter reporting. Compugen and BioMarin set dates for Q3 2026 results in early November, Eli Lilly declared its fourth-quarter dividend, and Evogene outlined its attendance at two European conferences. Aurora Cannabis said a securities regulator dismissed a challenge from Curaleaf to its at-the-market program.
Abbott
Abbott launches whole-genome sequencing Oncodetect® molecular residual disease (MRD) test to detect traces of cancer during and after treatment
Abbott launched a next-generation Oncodetect MRD test built on whole-genome sequencing and MAESTRO technology, which the company says tracks up to 5,000 patient-specific variants with a limit of detection below one part per million under high-end inputs. The test is intended to detect traces of cancer during and after treatment.
Climb Bio, Inc.
Climb Bio Presents Initial PrisMN Phase 2 Data from Budoprutug in pMN at an Oral Session at ASN Kidney Week 2026
Climb Bio presented initial data from its Phase 2 PrisMN dose-escalation trial of budoprutug in primary membranous nephropathy at ASN Kidney Week 2026, reporting B-cell depletion, lower PLA2R antibody levels and immunologic remission at Week 12 in the 200 mg cohort. The company says early 600 mg data suggest greater drug exposure and deeper B-cell depletion, and that the drug has been generally well tolerated to date.
Aurora Cannabis Inc.
Aurora Cannabis Announces the Alberta Securities Commission has dismissed Curaleaf's Application and ruled in favour of the Company's At-the-Market Program
Aurora Cannabis said the Alberta Securities Commission dismissed Curaleaf's application concerning Aurora's at-the-market program. Aurora says the ruling confirms the program complies with securities laws.
Anixa Biosciences, Inc.
Anixa Biosciences Announces Completion of Treatment of Fifth Cohort in its Ovarian Cancer CAR-T Clinical Trial
Anixa Biosciences completed treatment of the fifth cohort in its ovarian cancer CAR-T trial, with patients receiving 1×10⁷ CAR-positive cells/kg, and says the first patient in that cohort showed stable disease 90 days after treatment. The company reports multiple patients surviving more than one year, one beyond two years, with no dose-limiting toxicities observed to date.
Evogene
Evogene to Participate in Upcoming BIO-Europe in Germany and Drug Discovery Chemistry Europe in Spain
Evogene will attend BIO-Europe in Cologne, Germany, and present a scientific poster at Drug Discovery Chemistry Europe in Barcelona, Spain. The appearances put the computational chemistry company in front of European partnering and drug discovery audiences.
Eli Lilly and Company
Lilly declares fourth-quarter 2026 dividend
Eli Lilly's board declared a fourth-quarter 2026 dividend of $1.73 per share on outstanding common stock. The dividend is payable on December 10, 2026.
Compugen Ltd.
Compugen to Release Third Quarter 2026 Results on Monday, November 9, 2026
Compugen will release its third quarter 2026 financial results on Monday, November 9, 2026. The clinical-stage cancer immunotherapy company describes itself as focused on AI-powered computational drug target discovery.
BioMarin Pharmaceutical Inc.
BioMarin to Host Third Quarter 2026 Financial Results Conference Call and Webcast on Monday, November 2, 2026, at 4:30pm ET
BioMarin CEO Alexander Hardy will host a conference call and webcast on Monday, November 2, 2026, at 4:30 p.m. ET to discuss third quarter 2026 results. The call sets the date for investors tracking the company's quarterly performance.
This roundup is written with AI assistance from the press releases listed above, using only what they state. The releases are the companies' own announcements, not The Digest Lab reporting.